Searchable abstracts of presentations at key conferences in endocrinology

ea0099ep571 | Reproductive and Developmental Endocrinology | ECE2024

Short and long-term efficacy of minoxidil on beard growth in a group of assigned female at birth transgender people on gender affirming hormone therapy

Marinelli Lorenzo , Bichiri Andreina , Ghigo Ezio , Motta Giovanna

Introduction: Minoxidil is a vasodilator drug used as topical treatment of androgenetic alopecia; however, its efficacy for beard enhancement is reported in cisgender men and in a case-report of a transgender assigned female at birth (t-AFAB) adolescent. This study aims to evaluate the short- and long-term efficacy of topical minoxidil in a group of t-AFAB people on gender affirming hormone therapy (GAHT) with testosterone.Materials and methods:...

ea0090oc4.1 | Oral Communications 4: Reproductive and Developmental Endocrinology | ECE2023

Gender-affirming hormone treatment: friend or foe? Long term follow-up of 755 transgender and gender diverse people

Spaggiari Giorgia , Marinelli Lorenzo , Cacciani Marta , Scipio Sofia , Bichiri Andreina , Profeta Alessandra , Granata Antonio Raffaele Michele , Ghigo Ezio , Simoni Manuela , Motta Giovanna , Santi Daniele

Background: Gender-affirming hormone treatment (GAHT) is the cornerstone in the therapeutic management of transgender and gender diverse (TGD) people, which are currently classified as transgender assigned-female-at birth (t-AFAB) and assigned-male-at birth (t-AMAB) subjects. Due to its hormonal nature, GAHT is commonly handled by the endocrinologist and available guidelines on this topic mimic the recommendations for cis-gender hypogonadal populations. However, the GAHT long ...